Rutin targets IRG1-itaconate-Nrf2 axis, significantly reducing CCl₄-induced liver fibrosis in mice
Background
Chronic liver injury often culminates in liver fibrosis, a progressive condition characterized by persistent inflammation, oxidative stress, and excessive extracellular matrix deposition. Current therapeutic options are limited, highlighting the urgent need for novel anti-fibrotic agents. The natural flavonoid rutin has demonstrated hepatoprotective potential through its antioxidant and anti-inflammatory properties, yet its precise anti-fibrotic mechanisms, particularly involving the immune-responsive gene 1 (IRG1), remain largely unexplored. Understanding this specific pathway could unlock new strategies for treating advanced liver disease.
Study Design
Researchers investigated rutin's effects in a carbon tetrachloride (CCl₄)-induced mouse model of liver fibrosis. Mice were administered CCl₄ to induce fibrosis, with a subset receiving rutin treatment. The study employed IRG1-deficient mice to specifically assess the gene's involvement in rutin's protective actions. Hepatic injury, collagen deposition, inflammatory activation, and oxidative stress were comprehensively evaluated using histological, biochemical, molecular, and transcriptomic approaches. Direct binding between rutin and IRG1 was further explored via molecular docking, molecular dynamics simulations, and the cellular thermal shift assay (CETSA).
Results
Rutin treatment consistently and markedly alleviated CCl₄-induced hepatic injury, fibrotic deposition, inflammatory cytokine production, and reactive oxygen species accumulation. Mechanistically, rutin was found to directly bind to and stabilize IRG1, which was associated with enhanced IRG1 enzymatic activity and a subsequent increase in endogenous itaconate production. This crucial interaction led to the robust activation of Nrf2-mediated antioxidant signaling pathways and a significant suppression of NLRP3 inflammasome activation. These coordinated responses collectively mitigated the progression of liver fibrosis. Importantly, the protective effects of rutin were largely abolished in IRG1-deficient mice, confirming IRG1 as an essential mediator for rutin-mediated hepatoprotection. This highlights a novel therapeutic target for liver fibrosis.
Rutin's protective effects against CCl₄-induced liver fibrosis were largely abolished in IRG1-deficient mice, confirming IRG1 as essential for its hepatoprotective action.
Key Findings
- Rutin treatment markedly alleviated CCl₄-induced hepatic injury and fibrotic deposition in mice.
- Rutin directly bound to and stabilized
IRG1, enhancing its enzymatic activity and increasing itaconate production. - Rutin activated
Nrf2-mediated antioxidant signaling and suppressedNLRP3inflammasome activation. - The anti-fibrotic effects of rutin were largely abolished in
IRG1-deficient mice, confirmingIRG1's essential role.
Why It Matters
These findings establish rutin as a promising anti-fibrotic agent, offering a novel mechanistic understanding through its targeting of the IRG1/itaconate axis. For individuals facing liver fibrosis, this research suggests a potential natural compound that could coordinate both antioxidant and anti-inflammatory responses, addressing multiple facets of the disease. While this is a preclinical animal study, it provides a strong foundation for future human trials, potentially leading to new therapeutic strategies. The identification of the IRG1/itaconate/Nrf2 pathway as a key target for rutin opens avenues for developing more effective interventions for liver fibrosis, potentially as an adjunct to existing treatments or as a standalone therapy in early stages. Further research is needed to translate these findings into specific human protocols.
rutin
liver-fibrosis
ccl4
irg1
itaconate
nrf2